To further demonstrate the importance of THEM6 in clinical PCa, we performed IHC on a tissue microarray (TMA, n = 297, Table EV5) comprised of tumours obtained from treatment‐naïve (Untreated), treatment‐responsive (neoadjuvant hormonal therapy, NHT‐treated), treatment‐resistant (CRPC) and neuroendocrine (NEPC) PCa patients (Figs 6E and EV6C). This evidence concerns the gene THEM6 and neoplasm.